NCT03142334, Pembrolizumab, nierselkarsinoom

Pembrolizumab is goedgekeur vir adjuvante behandeling van nierselkarsinoom

Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or high risk of recurrence after ..

KEYTRUDA, Lenvatinib, Lenvatinib plus pembrolizumab, Lenvima, Merck, nierselkarsinoom

Die FDA het die kombinasie van lenvatinib en pembrolizumab vir gevorderde nierselkarsinoom goedgekeur

August 2021: The combination of lenvatinib (Lenvima, Eisai) and pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the first-line treatment of adult patients with advanced renal cell carcinom..

AVEO Pharmaceuticals, Fotivda, kinase inhibeerder, refractory advanced renal cell carcinoma, nierselkarsinoom, tivozanib

Tivozanib is deur die FDA goedgekeur vir die behandeling van terugval of vuurvaste gevorderde nierselkarsinoom

August 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, has been approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more prior systemic the..

8 hoofoorsake van nierkanker

Many patients with kidney cancer do not know why they have this disease, meaning the causes of kidney cancer are relatively unknown. After the examination, they will be very surprised. Some even feel that the kidney is not a probl..